Lenvatinib | hsa00071 | Fatty acid degradation | 3.50E-02 | 4 | O75521, P00325, P11766, P33121 | ECI2, ADH1B, ADH5, ACSL1 | More | |
Lenvatinib | hsa00220 | Arginine biosynthesis | 3.83E-02 | 2 | P05089, P49448 | ARG1, GLUD2 | More | |
Lenvatinib | hsa00310 | Lysine degradation | 1.31E-03 | 2 | Q96KQ7, P51648 | EHMT2, ALDH3A2 | More | |
Lenvatinib | hsa00500 | Starch and sucrose metabolism | 2.67E-02 | 1 | P35573 | AGL | More | |
Lenvatinib | hsa00512 | Mucin type O-glycan biosynthesis | 4.86E-02 | 2 | O95395, Q9NY28 | GCNT3, GALNT8 | More | |
Lenvatinib | hsa00564 | Glycerophospholipid metabolism | 1.38E-02 | 3 | P48651, Q9Y6K0, P35790 | PTDSS1, CEPT1, CHKA | More | |
Lenvatinib | hsa00630 | Glyoxylate and dicarboxylate metabolism | 1.03E-04 | 2 | P40925, P15104 | MDH1, GLUL | More | |
Lenvatinib | hsa00830 | Retinol metabolism | 2.27E-03 | 5 | P00325, P11766, P00352, Q9BPW9, O75911 | ADH1B, ADH5, ALDH1A1, DHRS9, DHRS3 | More | |
Lenvatinib | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 1.82E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa01522 | Endocrine resistance | 2.16E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa02010 | ABC transporters | 4.48E-02 | 1 | Q8IZY2 | ABCA7 | More | |
Lenvatinib | hsa03040 | Spliceosome | 9.64E-06 | 13 | Q14562, O43143, O60508, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O75643 | DHX8, DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, ASCC3L1 | More | |
Lenvatinib | hsa04010 | MAPK signaling pathway | 4.15E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04012 | ErbB signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04014 | Ras signaling pathway | 3.82E-03 | 8 | P04049, Q9NRA1, Q13009, P0DP23, P62873, P63218, P50151, P19174 | RAF1, PDGFC, TIAM1, CALM1, GNB1, GNG5, GNG10, PLCG1 | More | |
Lenvatinib | hsa04015 | Rap1 signaling pathway | 2.99E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04022 | cGMP-PKG signaling pathway | 3.15E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04024 | cAMP signaling pathway | 2.49E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04060 | Cytokine-cytokine receptor interaction | 5.34E-03 | 11 | P14784, P27930, P14778, P26842, Q06643, Q13651, P25024, Q9UBD3, P47992, P09341, P01730 | IL2RB, IL1R2, IL1R1, CD27, LTB, IL10RA, CXCR1, XCL2, XCL1, CXCL1, CD4 | More | |
Lenvatinib | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 1.32E-02 | 6 | P09341, P25024, P47992, Q9UBD3, Q13651, P14784 | CXCL1, CXCR1, XCL1, XCL2, IL10RA, IL2RB | More | |
Lenvatinib | hsa04062 | Chemokine signaling pathway | 1.82E-05 | 16 | P25024, P09341, P47992, Q9UBD3, P07948, P19174, P62873, P63218, P50151, P43250, Q08881, Q13009, P14598, P42224, P04049, P25963 | CXCR1, CXCL1, XCL1, XCL2, LYN, PLCG1, GNB1, GNG5, GNG10, GRK6, ITK, TIAM1, NCF1, STAT1, RAF1, NFKBIA | More | |
Lenvatinib | hsa04064 | NF-kappa B signaling pathway | 5.48E-07 | 20 | P10415, Q12933, O00463, P14778, P01584, P01375, Q04759, Q9UDY8, Q13077, P10145, P19784, Q16548, P07948, P06239, Q8WV28, Q13315, P24522, P09341, Q06643, Q9NQC7 | BCL2, TRAF2, TRAF5, IL1R1, IL1B, TNF, PRKCQ, MALT1, TRAF1, IL8, CSNK2A2, BCL2A1, LYN, LCK, BLNK, ATM, GADD45A, CXCL1, LTB, CYLD | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.713 | Q9Y6K0 | CEPT1 | Choline/ethanolaminephosphotransferase 1 | Q12933 | TRAF2 | TNF receptor-associated factor 2 | 0.762 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.932 | P06239 | LCK | Tyrosine-protein kinase Lck | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.718 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | O00463 | TRAF5 | TNF receptor-associated factor 5 | 0.717 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.766 | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01584 | IL1B | Interleukin-1 beta | 0.807 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q04759 | PRKCQ | Protein kinase C theta type | 0.776 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | 0.723 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.796 | Q9Y6K0 | CEPT1 | Choline/ethanolaminephosphotransferase 1 | P10145 | IL8 | Interleukin-8 | 0.758 | Q9Y6K0 | CEPT1 | Choline/ethanolaminephosphotransferase 1 | P19784 | CSNK2A2 | Casein kinase II subunit alpha' | 0.802 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.958 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | -0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | P07948 | LYN | Tyrosine-protein kinase Lyn | -0.701 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q8WV28 | BLNK | B-cell linker protein | -0.704 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q13315 | ATM | Serine-protein kinase ATM | 0.723 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.819 | P06239 | LCK | Tyrosine-protein kinase Lck | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.724 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.734 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09341 | CXCL1 | Growth-regulated alpha protein | 0.788 | P06239 | LCK | Tyrosine-protein kinase Lck | P09341 | CXCL1 | Growth-regulated alpha protein | -0.805 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P09341 | CXCL1 | Growth-regulated alpha protein | -0.789 | P06239 | LCK | Tyrosine-protein kinase Lck | Q06643 | LTB | Lymphotoxin-beta | 0.846 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q9NQC7 | CYLD | Ubiquitin carboxyl-terminal hydrolase CYLD | 0.799 |
|
Lenvatinib | hsa04068 | FoxO signaling pathway | 1.99E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04070 | Phosphatidylinositol signaling system | 2.93E-02 | 4 | P19174, P0DP23, P23743, P27987 | PLCG1, CALM1, DGKA, ITPKB | More | |
Lenvatinib | hsa04071 | Sphingolipid signaling pathway | 4.86E-03 | 6 | P04049, P21453, Q9H228, Q13362, Q9BX95, P10415 | RAF1, S1PR1, EDG8, PPP2R5C, SGPP1, BCL2 | More | |
Lenvatinib | hsa04072 | Phospholipase D signaling pathway | 2.82E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04080 | Neuroactive ligand-receptor interaction | 1.00E-02 | 7 | P08311, Q15722, P21453, Q9H228, O00398, P21730, P07550 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, ADRB2 | More | |
Lenvatinib | hsa04140 | Autophagy - animal | 2.95E-02 | 5 | P04049, P22694, Q14643, P10415, Q04759 | RAF1, PRKACB, ITPR1, BCL2, PRKCQ | More | |
Lenvatinib | hsa04141 | Protein processing in endoplasmic reticulum | 8.60E-03 | 6 | P30101, P60604, P11142, P08238, Q9H173, Q9UNL2 | PDIA3, UBE2G2, HSPA8, HSP90AB1, SIL1, SSR3 | More | |
Lenvatinib | hsa04144 | Endocytosis | 2.81E-02 | 6 | Q13191, P11142, P25024, P43250, P14784, Q9Y5X3 | CBLB, HSPA8, CXCR1, GRK6, IL2RB, SNX5 | More | |
Lenvatinib | hsa04145 | Phagosome | 9.44E-04 | 11 | P11215, Q15080, P14598, Q71U36, Q13509, P68371, Q13488, P05164, O60603, P35443, P13765 | ITGAM, NCF4, NCF1, TUBA1A, TUBB3, TUBB2C, TCIRG1, MPO, TLR2, THBS4, HLA-DOB | More | |
Lenvatinib | hsa04150 | mTOR signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04210 | Apoptosis | 3.76E-03 | 8 | Q13315, P10415, O76075, P24522, Q16548, P43234, Q14643, P04049 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ITPR1, RAF1 | More | |
Lenvatinib | hsa04218 | Cellular senescence | 2.49E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04260 | Cardiac muscle contraction | 4.70E-02 | 2 | P09493, P14927 | TPM1, UQCRB | More | |
Lenvatinib | hsa04270 | Vascular smooth muscle contraction | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04340 | Hedgehog signaling pathway | 3.09E-02 | 3 | P22694, Q13635, P10415 | PRKACB, PTCH1, BCL2 | More | |
Lenvatinib | hsa04360 | Axon guidance | 2.49E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04370 | VEGF signaling pathway | 8.29E-03 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04371 | Apelin signaling pathway | 3.46E-04 | 8 | P62873, P63218, P50151, P04049, Q13370, Q14344, P84022, P0DP23 | GNB1, GNG5, GNG10, RAF1, PDE3B, GNA13, SMAD3, CALM1 | More | |
Lenvatinib | hsa04380 | Osteoclast differentiation | 2.05E-03 | 12 | Q9NQC7, Q9UQC2, Q16539, P23458, P06239, P01584, P14778, O75015, Q8WV28, P01375, Q15080, P78324 | CYLD, GAB2, MAPK14, JAK1, LCK, IL1B, IL1R1, FCGR3B, BLNK, TNF, NCF4, SIRPA | More | |
Lenvatinib | hsa04510 | Focal adhesion | 3.48E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04540 | Gap junction | 2.22E-03 | 5 | Q13509, P68371, Q71U36, P04049, Q9NRA1 | TUBB3, TUBB2C, TUBA1A, RAF1, PDGFC | More | |
Lenvatinib | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 1.99E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04610 | Complement and coagulation cascades | 2.30E-06 | 2 | P0C0L4, P05107 | C4A, ITGB2 | More | |
Lenvatinib | hsa04612 | Antigen processing and presentation | 2.20E-03 | 6 | P13765, P01730, P26715, P26717, Q13241, P01732 | HLA-DOB, CD4, KLRC1, KLRC2, KLRD1, CD8A | More | |
Lenvatinib | hsa04613 | Neutrophil extracellular trap formation | 6.02E-04 | 16 | P04049, O60603, P05164, P08246, Q9UM07, Q13547, Q92769, P0C0S5, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | RAF1, TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AFZ, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | |
Lenvatinib | hsa04614 | Renin-angiotensin system | 2.74E-02 | 3 | P15144, P08311, O75787 | ANPEP, CTSG, ATP6AP2 | More | |
Lenvatinib | hsa04622 | RIG-I-like receptor signaling pathway | 1.06E-02 | 2 | Q12933, P10145 | TRAF2, IL8 | More | |
Lenvatinib | hsa04623 | Cytosolic DNA-sensing pathway | 2.59E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | |
Lenvatinib | hsa04625 | C-type lectin receptor signaling pathway | 1.88E-03 | 10 | Q9ULY5, P04049, P01584, Q9NQC7, P20749, Q14643, P01375, Q13191, P0DP24, Q16539 | CLEC4E, RAF1, IL1B, CYLD, BCL3, ITPR1, TNF, CBLB, CALM2, MAPK14 | More | |
Lenvatinib | hsa04630 | JAK-STAT signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04640 | Hematopoietic cell lineage | 1.16E-04 | 14 | P13612, P14778, P27930, P15144, P11836, P25063, P07766, P09693, P01732, P01730, P09564, P13765, P01375, P01584 | ITGA4, IL1R1, IL1R2, ANPEP, MS4A1, CD24, CD3E, CD3G, CD8A, CD4, CD7, HLA-DOB, TNF, IL1B | More | |
Lenvatinib | hsa04650 | Natural killer cell mediated cytotoxicity | 8.66E-06 | 12 | P01375, P78314, P06239, O60880, P20963, P04049, Q13241, P26718, O14931, O75015, P26717, P26715 | TNF, SH3BP2, LCK, SH2D1A, CD247, RAF1, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.761 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.823 | P06239 | LCK | Tyrosine-protein kinase Lck | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.906 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.869 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.74 | P04049 | RAF1 | RAF proto-oncogene serine/threonine-protein kinase | P04049 | RAF1 | RAF proto-oncogene serine/threonine-protein kinase | 1 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.82 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.863 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.91 | P06239 | LCK | Tyrosine-protein kinase Lck | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.886 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.762 | P06239 | LCK | Tyrosine-protein kinase Lck | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.732 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.92 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.846 | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.853 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.846 | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.853 |
|
Lenvatinib | hsa04657 | IL-17 signaling pathway | 1.56E-02 | 8 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375, P01584 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF, IL1B | More | |
Lenvatinib | hsa04658 | Th1 and Th2 cell differentiation | 1.66E-10 | 14 | Q04759, P07766, P20963, P09693, Q16539, P01730, P06239, Q14765, P23771, Q9UL17, P14784, P13765, P23458, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, CD4, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, JAK1, RUNX3 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q04759 | PRKCQ | Protein kinase C theta type | 0.776 | P07948 | LYN | Tyrosine-protein kinase Lyn | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.824 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.74 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.835 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.744 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.883 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | P07948 | LYN | Tyrosine-protein kinase Lyn | P06239 | LCK | Tyrosine-protein kinase Lck | -0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | -0.777 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q14765 | STAT4 | Signal transducer and activator of transcription 4 | 0.742 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.763 | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.85 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.872 | P07948 | LYN | Tyrosine-protein kinase Lyn | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.719 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.735 | P07948 | LYN | Tyrosine-protein kinase Lyn | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.771 | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.785 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.795 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 0.757 | P07948 | LYN | Tyrosine-protein kinase Lyn | Q13761 | RUNX3 | Runt-related transcription factor 3 | -0.855 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13761 | RUNX3 | Runt-related transcription factor 3 | 0.85 |
|
Lenvatinib | hsa04659 | Th17 cell differentiation | 1.26E-10 | 20 | P25963, Q04759, Q16539, P19174, P01730, P06239, P42224, P14784, P13765, P14778, Q9UL17, P23771, P84022, Q13485, P01584, P08238, P07766, P09693, P20963, P23458 | NFKBIA, PRKCQ, MAPK14, PLCG1, CD4, LCK, STAT1, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, SMAD3, SMAD4, IL1B, HSP90AB1, CD3E, CD3G, CD247, JAK1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.818 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q04759 | PRKCQ | Protein kinase C theta type | 0.776 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.883 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.869 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | P07948 | LYN | Tyrosine-protein kinase Lyn | P06239 | LCK | Tyrosine-protein kinase Lck | -0.701 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | 0.783 | P07948 | LYN | Tyrosine-protein kinase Lyn | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.771 | P06239 | LCK | Tyrosine-protein kinase Lck | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.727 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.717 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.785 | P06239 | LCK | Tyrosine-protein kinase Lck | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.777 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | 0.795 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.766 | P07948 | LYN | Tyrosine-protein kinase Lyn | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.714 | P06239 | LCK | Tyrosine-protein kinase Lck | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.782 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.872 | P07948 | LYN | Tyrosine-protein kinase Lyn | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.719 | P06239 | LCK | Tyrosine-protein kinase Lck | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.866 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.735 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.763 | P06239 | LCK | Tyrosine-protein kinase Lck | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.77 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | 0.85 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | -0.77 | P07948 | LYN | Tyrosine-protein kinase Lyn | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.729 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01584 | IL1B | Interleukin-1 beta | 0.807 | P07948 | LYN | Tyrosine-protein kinase Lyn | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.782 | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | 1 | P07948 | LYN | Tyrosine-protein kinase Lyn | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.824 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.835 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.744 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.74 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 0.757 |
|
Lenvatinib | hsa04660 | T cell receptor signaling pathway | 2.43E-07 | 16 | P01375, Q9UDY8, Q04759, P10747, O95267, Q08881, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, P04049, Q16539, P49841 | TNF, MALT1, PRKCQ, CD28, RASGRP1, ITK, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, RAF1, MAPK14, GSK3B | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | 0.723 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | P06239 | LCK | Tyrosine-protein kinase Lck | Q04759 | PRKCQ | Protein kinase C theta type | 0.779 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q04759 | PRKCQ | Protein kinase C theta type | 0.776 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P10747 | CD28 | T-cell-specific surface glycoprotein CD28 | 0.794 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.852 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.866 | P06239 | LCK | Tyrosine-protein kinase Lck | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.774 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | 0.746 | P06239 | LCK | Tyrosine-protein kinase Lck | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.928 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.74 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.835 | P06239 | LCK | Tyrosine-protein kinase Lck | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.752 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | 0.744 | P06239 | LCK | Tyrosine-protein kinase Lck | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.746 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.781 | P06239 | LCK | Tyrosine-protein kinase Lck | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.841 | P42330 | AKR1C3 | Aldo-keto reductase family 1 member C3 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.92 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.803 | P06239 | LCK | Tyrosine-protein kinase Lck | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.714 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | P04049 | RAF1 | RAF proto-oncogene serine/threonine-protein kinase | P04049 | RAF1 | RAF proto-oncogene serine/threonine-protein kinase | 1 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.883 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.812 |
|
Lenvatinib | hsa04662 | B cell receptor signaling pathway | 4.47E-03 | 5 | P42338, P60033, P07948, Q8N149, P04049 | PIK3CB, CD81, LYN, LILRA2, RAF1 | More | |
Lenvatinib | hsa04664 | Fc epsilon RI signaling pathway | 1.24E-03 | 5 | P04141, P07948, P19174, P04049, P09917 | CSF2, LYN, PLCG1, RAF1, ALOX5 | More | |
Lenvatinib | hsa04666 | Fc gamma R-mediated phagocytosis | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04713 | Circadian entrainment | 2.18E-02 | 4 | P0DP23, P62873, P63218, P50151 | CALM1, GNB1, GNG5, GNG10 | More | |
Lenvatinib | hsa04720 | Long-term potentiation | 1.66E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04722 | Neurotrophin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04724 | Glutamatergic synapse | 8.84E-04 | 5 | O15399, P62873, P63218, P50151, P15104 | GRIN2D, GNB1, GNG5, GNG10, GLUL | More | |
Lenvatinib | hsa04726 | Serotonergic synapse | 5.74E-03 | 5 | P62873, P63218, P50151, P09917, P04049 | GNB1, GNG5, GNG10, ALOX5, RAF1 | More | |
Lenvatinib | hsa04727 | GABAergic synapse | 5.11E-04 | 4 | P62873, P63218, P50151, P15104 | GNB1, GNG5, GNG10, GLUL | More | |
Lenvatinib | hsa04730 | Long-term depression | 1.95E-02 | 3 | Q14344, P04049, P07948 | GNA13, RAF1, LYN | More | |
Lenvatinib | hsa04744 | Phototransduction | 9.21E-03 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | |
Lenvatinib | hsa04750 | Inflammatory mediator regulation of TRP channels | 1.17E-02 | 8 | P14778, P01584, P51828, P22694, Q16539, Q14643, Q04759, P0DP24 | IL1R1, IL1B, ADCY7, PRKACB, MAPK14, ITPR1, PRKCQ, CALM2 | More | |
Lenvatinib | hsa04810 | Regulation of actin cytoskeleton | 3.81E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04910 | Insulin signaling pathway | 1.49E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04912 | GnRH signaling pathway | 2.74E-02 | 7 | P51828, Q16539, Q9Y6R4, Q14643, P0DP24, P22694, P04049 | ADCY7, MAPK14, MAP3K4, ITPR1, CALM2, PRKACB, RAF1 | More | |
Lenvatinib | hsa04914 | Progesterone-mediated oocyte maturation | 2.16E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04915 | Estrogen signaling pathway | 2.99E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04916 | Melanogenesis | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04917 | Prolactin signaling pathway | 6.63E-03 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04919 | Thyroid hormone signaling pathway | 1.82E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04921 | Oxytocin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04922 | Glucagon signaling pathway | 4.23E-02 | 4 | P22694, P06737, Q12778, Q14643 | PRKACB, PYGL, FOXO1, ITPR1 | More | |
Lenvatinib | hsa04924 | Renin secretion | 1.04E-02 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | |
Lenvatinib | hsa04926 | Relaxin signaling pathway | 2.32E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04928 | Parathyroid hormone synthesis, secretion and action | 1.60E-02 | 5 | Q14643, P22694, P23771, P04049, P10415 | ITPR1, PRKACB, GATA3, RAF1, BCL2 | More | |
Lenvatinib | hsa04929 | GnRH secretion | 4.98E-03 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04935 | Growth hormone synthesis, secretion and action | 2.16E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa04964 | Proximal tubule bicarbonate reclamation | 4.48E-02 | 1 | P00918 | CA2 | More | |
Lenvatinib | hsa04966 | Collecting duct acid secretion | 4.48E-02 | 1 | P00918 | CA2 | More | |
Lenvatinib | hsa05012 | Parkinson disease | 1.77E-02 | 6 | P60604, P19174, P0DP23, Q71U36, Q13509, P68371 | UBE2G2, PLCG1, CALM1, TUBA1A, TUBB3, TUBB2C | More | |
Lenvatinib | hsa05017 | Spinocerebellar ataxia | 2.22E-02 | 4 | Q92915, O15399, P42338, P21796 | FGF14, GRIN2D, PIK3CB, VDAC1 | More | |
Lenvatinib | hsa05032 | Morphine addiction | 2.18E-02 | 4 | P62873, P63218, P50151, Q13370 | GNB1, GNG5, GNG10, PDE3B | More | |
Lenvatinib | hsa05034 | Alcoholism | 2.49E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 1.08E-02 | 4 | P25963, Q13488, P19174, P07948 | NFKBIA, TCIRG1, PLCG1, LYN | More | |
Lenvatinib | hsa05130 | Pathogenic Escherichia coli infection | 3.19E-02 | 6 | Q71U36, P16333, Q13509, P68371, Q14344, P25963 | TUBA1A, NCK1, TUBB3, TUBB2C, GNA13, NFKBIA | More | |
Lenvatinib | hsa05132 | Salmonella infection | 1.82E-02 | 8 | P25963, P08238, P04049, O75369, Q71U36, Q13509, P68371, P49754 | NFKBIA, HSP90AB1, RAF1, FLNB, TUBA1A, TUBB3, TUBB2C, VPS41 | More | |
Lenvatinib | hsa05133 | Pertussis | 4.24E-05 | 3 | P05107, P10145, P0C0L4 | ITGB2, IL8, C4A | More | |
Lenvatinib | hsa05134 | Legionellosis | 4.75E-02 | 3 | P25963, P11215, P11142 | NFKBIA, ITGAM, HSPA8 | More | |
Lenvatinib | hsa05140 | Leishmaniasis | 3.10E-03 | 13 | P13612, O75015, P14598, P11215, P23458, P42224, P13765, O60603, P25963, P01375, P01584, Q16539, Q15080 | ITGA4, FCGR3B, NCF1, ITGAM, JAK1, STAT1, HLA-DOB, TLR2, NFKBIA, TNF, IL1B, MAPK14, NCF4 | More | |
Lenvatinib | hsa05143 | African trypanosomiasis | 2.03E-02 | 2 | P69905, P68871 | HBA2, HBB | More | |
Lenvatinib | hsa05144 | Malaria | 1.89E-04 | 10 | P60033, P69905, P68871, O60603, P01375, P05107, P35443, P01584, P10145, P26718 | CD81, HBA2, HBB, TLR2, TNF, ITGB2, THBS4, IL1B, IL8, KLRK1 | More | |
Lenvatinib | hsa05146 | Amoebiasis | 1.86E-03 | 10 | P01584, P09341, P14778, P27930, P01375, O60603, P05089, P22694, P12814, P08311 | IL1B, CXCL1, IL1R1, IL1R2, TNF, TLR2, ARG1, PRKACB, ACTN1, CTSG | More | |
Lenvatinib | hsa05150 | Staphylococcus aureus infection | 9.70E-04 | 3 | P0C0L4, P13646, P05107 | C4A, KRT13, ITGB2 | More | |
Lenvatinib | hsa05152 | Tuberculosis | 3.98E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa05160 | Hepatitis C | 1.99E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa05161 | Hepatitis B | 1.99E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa05163 | Human cytomegalovirus infection | 3.15E-03 | 9 | P04049, P25963, P62873, P63218, P50151, P0DP23, Q14344, P30101, P01568 | RAF1, NFKBIA, GNB1, GNG5, GNG10, CALM1, GNA13, PDIA3, IFNA21 | More | |
Lenvatinib | hsa05164 | Influenza A | 3.65E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 2.04E-05 | 11 | P01568, P42224, P25963, P62873, P63218, P50151, P19174, P04049, P07948, P04141, P0DP23 | IFNA21, STAT1, NFKBIA, GNB1, GNG5, GNG10, PLCG1, RAF1, LYN, CSF2, CALM1 | More | |
Lenvatinib | hsa05168 | Herpes simplex virus 1 infection | 3.79E-02 | 9 | P25963, P01568, P42224, Q07955, Q01130, Q13243, P30101, Q13398, O75820 | NFKBIA, IFNA21, STAT1, SFRS1, SFRS2, SFRS5, PDIA3, ZNF211, ZNF189 | More | |
Lenvatinib | hsa05169 | Epstein-Barr virus infection | 4.84E-03 | 10 | P13765, P01106, Q13547, O00463, P07948, Q13761, P24522, P07766, P09693, P20963 | HLA-DOB, MYC, HDAC1, TRAF5, LYN, RUNX3, GADD45A, CD3E, CD3G, CD247 | More | |
Lenvatinib | hsa05170 | Human immunodeficiency virus 1 infection | 2.44E-03 | 9 | P04049, P62873, P63218, P50151, P0DP23, P30101, P01568, P25963, P19174 | RAF1, GNB1, GNG5, GNG10, CALM1, PDIA3, IFNA21, NFKBIA, PLCG1 | More | |
Lenvatinib | hsa05200 | Pathways in cancer | 1.99E-03 | 15 | P08238, P42224, P25963, P19174, P43246, P84022, P20585, P62873, P63218, P50151, Q14344, O75293, P0DP23, P01568, P14784 | HSP90AB1, STAT1, NFKBIA, PLCG1, MSH2, SMAD3, MSH3, GNB1, GNG5, GNG10, GNA13, GADD45B, CALM1, IFNA21, IL2RB | More | |
Lenvatinib | hsa05202 | Transcriptional misregulation in cancer | 8.91E-04 | 18 | Q12778, Q13315, P17844, P14780, P27930, Q16548, Q13077, O15550, P35226, P05164, P12838, P08246, Q9C0K0, P41182, Q13547, Q92769, P12980, P24522 | FOXO1, ATM, DDX5, MMP9, IL1R2, BCL2A1, TRAF1, UTX, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, HDAC1, HDAC2, LYL1, GADD45A | More | |
Lenvatinib | hsa05205 | Proteoglycans in cancer | 3.48E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa05206 | MicroRNAs in cancer | 3.15E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa05210 | Colorectal cancer | 1.66E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa05211 | Renal cell carcinoma | 1.16E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa05212 | Pancreatic cancer | 9.52E-03 | 4 | P04049, P42224, P84022, O75293 | RAF1, STAT1, SMAD3, GADD45B | More | |
Lenvatinib | hsa05213 | Endometrial cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa05214 | Glioma | 7.45E-03 | 4 | P0DP23, P04049, P19174, O75293 | CALM1, RAF1, PLCG1, GADD45B | More | |
Lenvatinib | hsa05215 | Prostate cancer | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa05217 | Basal cell carcinoma | 3.50E-02 | 4 | Q13635, P49841, Q9UJU2, P24522 | PTCH1, GSK3B, LEF1, GADD45A | More | |
Lenvatinib | hsa05218 | Melanoma | 6.63E-03 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa05219 | Bladder cancer | 4.98E-03 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa05220 | Chronic myeloid leukemia | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa05221 | Acute myeloid leukemia | 8.29E-03 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa05223 | Non-small cell lung cancer | 6.63E-03 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa05224 | Breast cancer | 1.49E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa05225 | Hepatocellular carcinoma | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa05226 | Gastric cancer | 8.29E-03 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa05230 | Central carbon metabolism in cancer | 9.95E-03 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa05231 | Choline metabolism in cancer | 1.33E-02 | 1 | P04049 | RAF1 | More | |
Lenvatinib | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 3.98E-05 | 12 | O95267, P07766, P20963, P09693, P06239, P04049, P23458, O60603, P10747, Q04759, Q16539, P01730 | RASGRP1, CD3E, CD247, CD3G, LCK, RAF1, JAK1, TLR2, CD28, PRKCQ, MAPK14, CD4 | More | |
Lenvatinib | hsa05321 | Inflammatory bowel disease | 8.20E-05 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, P01584 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL1B | More | |
Lenvatinib | hsa05323 | Rheumatoid arthritis | 1.60E-02 | 4 | P13765, P10747, P09341, O60603 | HLA-DOB, CD28, CXCL1, TLR2 | More | |
Lenvatinib | hsa05332 | Graft-versus-host disease | 3.63E-04 | 4 | P13765, P10747, P26715, Q13241 | HLA-DOB, CD28, KLRC1, KLRD1 | More | |
Lenvatinib | hsa05340 | Primary immunodeficiency | 2.19E-02 | 4 | P01730, P01732, P07766, P06239 | CD4, CD8A, CD3E, LCK | More | |
Lenvatinib | hsa05410 | Hypertrophic cardiomyopathy | 2.03E-02 | 2 | P26012, P09493 | ITGB8, TPM1 | More | |
Lenvatinib | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.48E-02 | 1 | P54284 | CACNB3 | More | |
Lenvatinib | hsa05414 | Dilated cardiomyopathy | 4.55E-02 | 2 | P54284, P26678 | CACNB3, PLN | More | |